Title of presentation:

The development of a synthetic branched peptide for fighting multi-resistant Gram-negative bacteria.

Speaker: Alessandro Pini, 

Conference website: http://berlin-conferences.com/home/

Seal of Excellence 2017
Certificate delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020 for the project "Non-clinical development of an antimicrobial drug to fight against resistant bacteria". The project has been presented in the area dedicated to supporting biotechnology of SMEs closing the gap from lab to market following evaluation by an international panel of independent experts. SetLance was scored as a high-quality project proposal in a highly competitive evaluation process.

Date: 22-25 April 2017

Location/Venue: Vienna, Austria

Website: http://www.eccmid.org/

Two oral presentations:

Dott. Chiara Falciani "An antimicrobial peptide to face multidrug-resistance emergency: synergies and mechanism of action underpinning efficacy".

 Dott. Alessandro Pini "The peptide SET-M33 as novel agent to neutralize and remove LPS in patients with sepsis".

The article ''A new hope for treating severe pneumonia'' featuring Setlance's antimicrobial peptide M33 was published on CORDIS (Community Research and Development Information Service), the European Commission’s primary public repository and portal to disseminate information on EU-funded research projects.

Read the whole article here:

https://cordis02europa02eu12o1zxp0.mentionusercontent.net/news/rcn/125622_en.html

October 2015. SetLance finances a PhD position in Biochemistry and Molecular Biology, XXXI cycle of the regional doctorate "Pegasus" (http://www.unisi.it/didattica/post-laurea/dottorati-ricerca/biochimica-e-biologia-molecolare-3). The selected student will be trained in SetLance laboratories working on projects related to the characterization and development of antimicrobial and anti-inflammatory peptides.

Recent developments in Bacterial Diseases, Bacteriology and Infectious Diseases.

Date: March 2015

Launch of BEAM Alliance – Biotechs of Europe innovating againts Anti-Microbial resistance

MISSION

The BEAM Alliance intends to:
•Regroup European emerging biotech companies who are involved in developing innovative products to tackle antimicrobial resistance ;
•Represent them with a unique voice to propose and support policies and regulatory solutions to member-identified problems;

In order to reinforce the attractiveness of this therapeutic area, support the development of new products and accelerate market access of such new products for the European patients. The Group seeks to collaborate with the existing community of stakeholders dedicated to implementing tangible solutions to combat this serious public health issue. Our mission is to recommend incentives that warrant further consideration and action to policymakers and others to overcome these challenges and address the threat of antibacterial resistance, now and in the future.

Project Progress Meetings

Invited communication at the 'Antibiotic Alternatives for the new millenium' Conference. London, November 2014